Scientific Poster Session III - Original Research

Abstract

The effectiveness of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in patients with metastatic breast cancer can significantly improve the patient's overall survival (OS) and progression-free survival (PFS) has been confirmed by many randomized controlled trials. However, the real-world efficacy and safety of CDK4/6i are still not clearly understood.

Research Question or Hypothesis: This study aimed to evaluate the safety and efficacy of CDK4/6i in the treatment of advanced breast cancer in a real-world clinical setting.

Study Design:

This study is a retrospective study, including patients diagnosed with advanced breast cancer who were treated at Tzu Chi Hospital in Taipei, Taiwan, from October 2019 to March 2023. These patients must have received at least one dose of abemaciclib, Palbociclib, or Ribociclib.

Methods:

The primary outcomes of treatment efficacy were OS, PFS, and objective response rate (ORR). In addition, adverse events were assessed as a secondary outcome.

Results:

This analysis included 95 patients with a mean age of 66.2 years. After a median follow-up of 15.5 months, the median PFS was 28.1 months (95% CI: 22.5-33.6). The results showed no significant difference in PFS between CDK4/6is treatments (p = 0.644). Seventy patients achieved an ORR (73.7%), with 24 patients (25.3%) achieving complete response (CR) and 46 patients (48.4%) achieving partial response (PR). The most common adverse events were fatigue (57.9%), leukopenia (48.4%), and anorexia (45.3%).

Conclusion:

Real-world study shows CDK4/6i exhibits survival benefits similar to those observed in clinical trials. In addition, there is no significant difference in efficacy among these three drugs.

Presenting Author

Authors